



European Lung Cancer Congress 2025

Abstract submission regulations and instructions

Regular abstract submission deadline
14 January 2025, 21:00hrs CET

(CET = Central European Time)

Late-breaking abstract deadline
18 February 2025, 21:00hrs CET

(CET = Central European Time)

All abstracts, including preliminary versions of those intended for late-breaking abstract status, must be submitted by the deadline of **21:00hrs CET on Tuesday, 14 January 2025**.

The deadline for the submission of finalised late-breaking abstracts is **21:00hrs CET on Tuesday, 18 February 2025**.

Abstract submission is free of charge and must be completed online only via the ELCC 2025 website.

Abstracts submitted by e-mail, post or fax will NOT be accepted.

Submission categories

- Advanced NSCLC
- Early stage NSCLC
- Imaging and staging
- Locally advanced NSCLC
- Mesothelioma
- Metastases to and from the lung
- Prevention, early detection, epidemiology, tobacco control
- SCLC
- Translational research
- Tumour biology and pathology
- General interest

Submission regulations and instructions

1. By submitting an abstract intended for presentation at the European Lung Cancer Congress (ELCC) 2025 **the first author** (= presenter) warrants that the **material has neither been, nor will be, previously published** in any publication in peer-review setting **or presented** at a meeting of any other scientific organisation prior to ELCC 2025.

Abstracts containing **updated data** with respect to a previous presentation may, however, be submitted to ELCC 2025. In this case, additional information must be given specifying clearly which new data will be presented, for example final analysis of primary endpoint(s) or intermediate statistical analysis. Authors must at the same time also supply information regarding the prior presentation for identification and comparison purposes, indicating the name of the meeting, year and/or publication number.

Violation of this policy will result in a rejection of the submitted abstract.

Should any similarities to prior presentations or publications exist, these must be explained in a covering letter, citing the ELCC 2025 abstract submission number, title and first author to the ELCC 2025 organisers by e-mail (programme@esmo.org). Except for exceptional circumstances, abstracts containing previously published material will be rejected.

Encore abstracts will NOT be accepted.

2. The first author may, but does not need to be, an ESMO or IASLC member.



- 3. With the submission of an abstract, and on behalf of him/herself and all co-authors, the first author (= presenter) undertakes to:**
- 3.1. Release full copyright to the European Society for Medical Oncology (ESMO) and the International Association for the Study of Lung Cancer (IASLC), jointly the “ELCC 2025 organisers” and give full permission for the abstract, if accepted, to be published in the ELCC 2025 Abstract book in electronic format, as well as published online on the ESMO, IASLC and publisher websites. Accepted abstracts will be published as a supplement of the official IASLC journal, *Journal of Thoracic Oncology*.
 - 3.2. Warrant that he/she is an investigator with a substantial involvement in the study presented in the abstract.
 - 3.3. Accept responsibility for the accuracy and confidentiality (see corresponding paragraph) of the submitted abstract.
 - 3.4. Confirm that all authors are aware of, and agree to, the content of the abstract and support the data therein; furthermore, the first author will be responsible for obtaining, and, upon request, showing proof that all authors have given their permission for the submission of the abstract and content therein as well as for the potential inclusion of the abstract in the official ELCC 2025 Press programme.
 - 3.5. Make all reasonable efforts to ensure the anonymity of any patient discussed in the abstracts.
 - 3.6. Be the contact person for all correspondence concerning the abstract and to keep co-authors duly informed about its status.
 - 3.7. Register for, and present his/her abstract in the official ELCC 2025 programme if it is selected for presentation as Proffered Paper (oral presentation), Mini Oral (short oral presentation) or Poster. The first author may nominate a co-author to present an abstract in his/her place provided that the replacement presenter is a listed co-author **independent of the sponsor (unless for data generated as mentioned in point 3.9 below)**. The name of the replacement must be submitted by e-mail to the ELCC 2025 organisers (programme@esmo.org) within thirty-six (36) hours of outcome notification. No shared first-authorship is possible: Each abstract can have one presenter only.
 - 3.8. The maximum number of abstract presentations throughout the ELCC 2025 by the same first and presenting author is **two (2)**, with options as follows:
 - 1 Proffered Paper (oral) presentation plus 1 Mini Oral
 - 1 Proffered Paper (oral) plus 1 Poster
 - 2 Mini Orals
 - 1 Mini Oral plus 1 Poster
 - 2 PostersAny additional Proffered Paper, Mini Oral or Poster must be presented by a listed co-author **independent of the sponsor (unless for data generated as mentioned in point 3.9 below)**.
 - 3.9. An author employed by the abstract sponsor or by a company (including pharmaceutical, diagnostic, data or AI companies) cannot act as the presenter or corresponding author of any work related to clinical or translational data, defined as data/parameters captured in interventional clinical studies (phase I-IV) and observational or real-world data series, involving patients. The presenter must be an independent, practising physician or independent investigator listed in the abstract author string. Authors employed by the sponsor or a company are allowed to present preclinical data. When the presenting investigator represents an independent entity contracted by the sponsor, this should be disclosed in the abstract submission process.
 - 3.10. Certify that the study reported in the abstract will not be presented as such during ELCC 2025 at any industry-related Industry Satellite Symposia prior to its presentation during the official ELCC 2025 programme.
 - 3.11. Indicate whether he/she agrees to participate in the official ELCC 2025 communication activities if the abstract is selected for coverage by the ELCC 2025 organisers and guarantee he/she is not subject to any restrictions by the institute he/she belongs to or by the scientific journals he/she may have submitted his/her research to.
 - 3.12. The first author must further confirm his/her presence at the official ELCC 2025 communication activities if selected; however, he/she may nominate a co-author to participate in the ELCC 2025 communication activities in his/her place provided that the replacement presenter is also a listed co-author independent of the sponsor who has also made a substantive contribution to the work. The name of the replacement must be submitted by email to the ESMO Press Office (pressoffice@esmo.org) within thirty-six (36) hours of acceptance and must confirm his/her attendance at the ELCC 2025 communication activities.
 - 3.13. Declare the name of the legal entity responsible for the governance, coordination and running of the study.
 - 3.14. Declare how the study detailed in the abstract was funded, for example by a pharmaceutical, biotech or other commercial company or by a Foundation or academic group, and to name the organisation(s) funding the study.



- 3.15. Ensure that all authors complete the “Declaration of Interest” statement identifying any financial/non-financial interest in products or processes involved in their activities, related or not, to the work submitted in the abstract. This includes stock ownership, membership on an advisory board or board of directors, corporate-sponsored research, or other substantive relationships such as employment with a pharmaceutical company or any other organisation. Should no valid disclosure statement be provided at submission, authors may, at the discretion of the ELCC 2025 Scientific Committee, be removed from the author string without further recourse to the authors.
- 3.16. Guarantee the scientific independence of the author or principle investigator (whichever is going to be the corresponding or presenting author) when presenting his/her data, and confirm that he/she has full control over the text of the submitted abstract, subsequent presentation (slides or poster) and content of the press release prepared by the ELCC 2025 organisers (if part of the official ELCC 2025 communication activities), and that he/she has not been influenced by any third party, including the sponsor of the study (unless for data generated as mentioned in point 3.9 above).
- 3.17. Indicate where applicable the number of the trial protocol (NIH or European equivalent) and the release date (when it was obtained).
- 3.18. Ensure that for all studies involving human or animal subjects, permission has been obtained from the relevant regulatory authority and that properly informed consent, where appropriate, has been given.
- 3.19. Indicate whether the abstract is submitted in association with an application for a Merit Travel Grant.
- 3.20. Acknowledge any editorial assistance in the writing of the abstract that was provided by a third party, providing the name of the writer and the company who provided this service.

4. Withdrawal of abstracts

If the first author wishes to withdraw his/her abstract from ELCC 2025 after the outcome notifications have been made available, he/she must submit a written request **within thirty-six (36) hours** to the ELCC 2025 organisers (programme@esmo.org). Any abstract withdrawal requests made after thirty-six (36) hours cannot be assured of removal from the ELCC 2025 Abstract book.

5. Correction of published abstracts

Minor corrections to the body of accepted abstracts may be possible if advised in writing to the ESMO Scientific Programmes Department (programme@esmo.org) **by Friday, 7 February 2025**. After this time, no changes will be possible at all unless requested by ESMO. Once the abstract has been published, no corrigenda will be considered unless the data published in the original abstract are proved to have a relevant and negative impact on the treatment of patients and/or the future of any related research. For changes related to the author string please see point 7.11. below

6. No-show policy

The abstract's first and presenting author who, without notice, is absent during the session when his/her abstract is presented will be barred from having abstracts accepted for the following European Lung Cancer Congress (ELCC). The name of the first and presenting author will also be forwarded to the programme committee of each of the organising societies.

7. Submission instructions

- 7.1. Each section of the online abstract submission system must be completed. Authors failing to give all information required in the online submission system will not have their abstract considered by the ELCC 2025 Scientific Committee.
- 7.2. Once each step is completed, the author must go to the Preview and Finish section and click *Finish Submission* to complete the process. Without clicking this option, the abstract will not be considered as submitted and will not be forwarded to the ELCC 2025 Scientific Committee for consideration.
- 7.3. Abstracts, with the exception of Trial in Progress (TiP abstracts, see below), should be structured in such a way as to include the following four (4) sections:
 - Background: An introductory sentence indicating the rationale of the study
 - Methods: A brief description of pertinent methodological procedures
 - Results: A summary of the results of the research
 - Conclusions: A statement of the main conclusions
- 7.4. The title of the abstract should include significant words that reflect the content of the abstract but not refer to the study results or conclusions. The ELCC 2025 Scientific Committee reserves the right to correct the title format without further recourse to the authors. Abstract title counts towards the overall character limit of 2,000.



- 7.5. Commercial names may not be used in the title of the abstract. Compounds should be mentioned with the generic name in lower case. Commercial names are admitted in the text, with the ® symbol, and if in brackets following the generic name, i.e. 'generic (Commercial®)'. The ELCC 2025 Scientific Committee reserves the right to substitute commercial names with generic names where necessary without further recourse to the authors.
- 7.6. The name(s) of the legal entity/entities responsible for the governance, coordination and running of the study detailed in the abstract, and the name(s) of the organisation(s) providing funding must be provided. This information will be published with the abstract.
- 7.7. Abbreviations may be used in the title and text of abstracts if they are defined. Terms must be spelt out in full at its first mention and followed with the abbreviation in parentheses. Particular care should be taken to identify complex chemotherapeutic regimens.
- 7.8. The character limit for all submitted abstracts is set at **2,000 excluding spaces**. This limit includes characters entered in the title, abstract body and table fields but not the author names and institutions.
- 7.9. Illustrations and graphs are NOT permitted. One brief and clear table counting for a default of 225 characters is accepted; however, the table itself must not be longer than 600 characters. More than one table may not be submitted under the guise of Table 1.1, 1.2 etc.
- 7.10. The maximum number of authors allowed per abstract is limited to twenty (20). Mailing addresses, academic degrees and professional positions such as Medical Director, CEO, CMO etc. must not be mentioned.
- 7.11. The names of all listed authors will be published in the order provided during submission. In exceptional cases, a maximum of one (1) new co-author, or, if strictly necessary, two (2) new co-authors may be added to the original author string, as long as they are accompanied by full "Declaration of Interests" statements. Changes may be requested in writing to the ESMO Scientific Programmes Department (programme@esmo.org) **by Friday, 7 February 2025**. Any requests for changes to the author string made after this time will not be included in the ELCC 2025 Abstract Book or the online programme. Once the abstract has been published, no corrigenda will be possible.
- 7.12. Authors must select the appropriate abstract submission category, however, the ELCC 2025 Scientific Committee reserves the right to re-categorise abstracts without further recourse to the authors.
- 7.13. Authors must select their preferred choice of presentation: Proffered Paper, Mini Oral or Poster; however, the decision of the ELCC 2025 Scientific Committee will be final.
- 7.14. The use of good English and proof-reading is essential. Once the abstract is submitted, online changes, corrections or rewording will not be possible. The ELCC 2025 Scientific Committee reserves the right to reject abstracts which are presented in poor English or to request an immediate revision by the first author.
- 7.15. Supplementary data such as manuscripts will not be accepted or forwarded to the ELCC 2025 Scientific Committee.
- 7.16. Abstracts on case reports will be rejected.

Presentation and publication of accepted abstracts

The ELCC 2025 Scientific Committee will select abstracts for presentation during the Congress based on the following possibilities:

- **Proffered Paper:** Oral presentation of original data of superior quality, followed by expert discussion and perspectives.
- **Mini Oral:** Short oral presentation of good quality data, followed by expert discussion and perspectives.
- **Poster:** Display session for review, discussion and questions. The presenting authors must be available for Q&A to represent their work.

All accepted abstracts will be published in the ELCC 2025 Abstract Book, a supplement to the official IASLC journal, *Journal of Thoracic Oncology*.

Detailed instructions for the preparation of slide presentations and posters will be made available on the ESMO website by early February ("Information for Presenters") along with scheduling notices.



Late-breaking abstracts (LBA)

Late-breaking abstracts may be submitted for high quality, new research findings from prospective interventional clinical trials or observational series or novel technologies with major implications for clinical practice and/or understanding and targeting of disease processes.

Only abstracts for which no conclusive data are available at the time of the abstract submission deadline of 14 January 2025 will be considered for late-breaking status. The work must not have been previously published in any publication in a peer review setting or presented at a meeting of any other scientific organisation prior to ELCC 2025.

The final late-breaking abstract deadline of 18 February 2025 is under no circumstances to be considered as an extension of the general submission deadline.

Late-breaking abstract submission instructions and review process:

- A preliminary abstract indicating the data expected to be available by the late-breaking abstract deadline must be submitted online by 14 January 2025 and the intent to submit a late-breaking abstract check-box must be ticked. The abstract must include the title, first author (with full contact details), objectives, rationale, methodology and anticipated data.
- The abstract length must not exceed the standard abstract length of 2,000 characters, excluding spaces. (Please see details in the general abstract submission instructions and regulations).
- The ELCC 2025 Scientific Committee will review all abstracts indicated as late-breaking and first authors will be advised whether the study has been identified as a potential late-breaking abstract.
- Authors receiving a positive outcome of this first review will be required to submit the entire abstract including author string, final results and conclusions plus any table (if applicable) online by the late-breaking abstract deadline, on 18 February 2025.
- All late-breaking abstract submissions must follow the standard submission regulations and instructions as outlined above.
- The ELCC 2025 Scientific Committee will re-consider the final abstract to determine whether it will be accepted as a late-breaking abstract for ELCC 2025. A decision will be made between the following three options:
 - **Accepted for Oral presentation:** during a Proffered Paper session.
 - **Accepted for Mini Oral:** during a Mini Oral session.
 - **Rejected:** Late-breaking abstracts that do not meet the criteria for Proffered Paper or Mini Oral presentation will not be accepted nor published.
- The presenters of accepted late-breaking abstracts will receive notification and further instructions by end-February 2025.
- Note: If a preliminary abstract marked for late-breaking submission is not updated by the late-breaking abstract deadline, the entire abstract will be automatically rejected.

Trial in progress abstracts

Trial in Progress (TiP) abstracts in all phases of clinical research (phases I to III) may be submitted to ELCC 2025.

It is expected that abstracts submitted as Trial in Progress are ongoing trials that have not reached any protocol-specified endpoints for analysis and consequently will only require the completion of two (2) sections:

1. Background
2. Trial design

Notes:

- Recruitment must have already begun or have been completed by the abstract submission deadline of 14 January 2025.
- Abstracts including results or preliminary data will be rejected.
- Trial in Progress abstracts will be considered for Poster outcome only.
- Encore TiP abstracts will NOT be accepted.



Embargo and Confidentiality policy

Data and information included in accepted abstracts is under embargo until the relevant embargo release date cited in the “Publication schedule for accepted abstracts”.

Data and information beyond what is included in all accepted abstracts, for example full data sets, may only be made public at the start of the official programme session during which the study is presented.

Abstracts accepted for presentation at ELCC 2025 must be considered confidential by the author, co-authors, institute(s), research sponsor(s) and ESMO until publicly released in connection with ELCC 2025.

In the event that any relevant party, including but not limited to, author, co-authors, institute(s), research sponsor(s), plans to issue a press release prior to presentation at ELCC 2025, ESMO requests that it adheres to the [Qualitative Sample Press Release](#) format by summarising abstract data in a qualitative rather than quantitative way, and avoiding interpretations about the implications of the data for clinical practice.

The relevant party is to submit to ESMO (programme@esmo.org, cc: media@esmo.org) written notification of the intention to issue a press release in advance of the release itself.

A note stating that full data has been submitted for presentation at ELCC 2025 should be added in the press release.

ESMO is available to provide guidance and feedback for the qualitative press release.

If the press release includes significantly more information than ESMO’s recommendations, the abstract’s placement in ELCC 2025 is subject to change.

ESMO reserves the right to share material under embargo with journalists on the authorised ESMO media list who have agreed to respect the ESMO embargo policy

Copyright

The ELCC 2025 organisers hold copyright of all abstracts accepted for the ELCC 2025 Congress and therefore abstracts cannot be made public prior to official publication.

ELCC 2025 copyright is lifted only if the abstract is not accepted for inclusion in the official ELCC 2025 Congress programme and/or publication in the Congress Abstract Book.

The submission of abstracts accepted for ELCC 2025 to subsequent conferences, organised either by ESMO, IASLC or third parties, requires the permission of the joint ELCC organizing partners. Requests must be addressed to (programme@esmo.org).

Commercial data mining of ELCC 2025 published abstracts requires the permission of the ELCC 2025 organisers and approval must be sought before inception of the project. Queries should be addressed to programme@esmo.org

Merit Travel Grants

A restricted number of Merit Travel Grants to ELCC 2025 are available, upon application, to first author (= presenter) who submit abstracts considered to be deserving of recognition. Candidates must be member of either ESMO or IASLC (or both) under the age of 40. Selection will be made by the ELCC 2025 Scientific Committee on a competitive basis from among the accepted abstracts.

The application for a Merit Travel Grant must be completed during the abstract submission process. Applicants will be required to reply to the following questions:

- How relevant to your current practice are the topics presented at this Congress?
- Have you attended any event on a similar topic in the last 3 years?
- How will your attendance at this Congress help with your professional development?
- How can your abstract contribute to the topics covered at this Congress?
- Have you recently been awarded an ESMO Award/Merit Travel Grant? If yes, for which event?

And to provide the following documents:

- A copy of the submitted abstract (NOTE: The applicant must be the first and presenting author)
- A readable photocopy of either identity card or passport



- A short curriculum vitae (max. 2 pages)

Incomplete applications will not be considered.

The ELCC 2025 organisers will provide the recipients with a subsidised travel ticket, subsidised accommodation and Congress registration.

Merit Travel Grant recipients must submit a report detailing the benefits of participating in ELCC 2025, by Tuesday 2 May 2025 to programme@esmo.org.